Sector News

Four years after buyout, Pfizer spins Icagen ion channel platform back out

July 2, 2015
Life sciences
Four years ago, Pfizer spent $56 million to bag Icagen and add its ion channel R&D platform and pipeline in North Carolina with its pain drug development arm in the U.K. But yesterday the pharma giant spun the platform back out to a small contract research group in Cambridge, MA, called XRPro Sciences, which will now combine its operations into an expanded research services operation that will cater to the biopharma industry.
 
XRPro CEO Richie Cunningham said that the deal includes a multi-year collaboration with the pharma giant, which gave up the platform for pennies on the dollar.
 
According to an 8-K filed this morning, XRPro is providing a $500,000 upfront, to be paid in installments through early 2016. Another $10.5 million in earn-outs is also up for grabs based on their financial performance.
 
The newly expanded company, which will operate as Icagen, will integrate ion channel and transporter drug tech that CSO Douglas Krafte and his team of 18 have been working on for years. Their work has covered a variety of fields, including cardiac arrhythmias, sickle cell anemia, asthma, epilepsy and pain. XRPro’s 10-person team, meanwhile, has been hawking its expertise in x-ray fluorescence with a variety of customers. The NIH provided a $3 million contract to develop strontium-selective therapies.
 
What did Pfizer get for its $56 million? Krafte points to one pain drug, PF-05089771–a small-molecule Nav1.7 therapy in the clinic–that came off the platform. Pfizer recently combined its pain and neuroscience pipelines into one division and launched a partnership with Eli Lilly to take a second shot at a Phase III for tanezumab. The pharma giant completed a huge reorganization several years ago but continues to trim and rearrange its R&D operations as it sees fit.
 
Biotech companies as well as “large pharmas are looking for efficiencies,” say Cunningham, and the new Icagen plans to provide that for both small molecule development–Icagen’s original area of expertise–along with new work related to biologics.
 
XRPro has been angling to start trading shares over the counter and files regular financial reports with the SEC.
 
According to Cunningham, XRPro Chairman Tim Tyson played a key role in landing the Icagen deal. The former CEO of Valeant–where Cunningham worked–went on to run the R&D services outfit Aptuit from 2008 to 2012 and helped make contact with execs at Pfizer.
 
By John Carroll
 

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.